Retatrutide and trizepatide constitute a new class of medications that target both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These dual receptor agonists https://cecilyxuxj406507.bloggactivo.com/37804876/new-glp-1-and-gip-receptor-agonists-retatrutide-and-trizepatide